Association between 4%-tetrasodium EDTA and sepsis in neonatal piglets: A retrospective cohort study
- PMID: 38400572
- DOI: 10.1002/jpen.2609
Association between 4%-tetrasodium EDTA and sepsis in neonatal piglets: A retrospective cohort study
Abstract
Background: Central line-associated bloodstream infections are a major concern for children with intestinal failure and in animal research using parenteral nutrition (PN). In neonatal piglets receiving PN, we compared sepsis, line occlusions, line replacements, mortality, and costs with and without the use of a 4%-tetrasodium ethylenediaminetetraacetic acid (T-EDTA) locking solution.
Methods: We performed a retrospective review of piglets with a central venous jugular catheter enrolled in 14-day exclusive PN (TPN) trials or in 7-day short bowel syndrome (SBS) trials, before and after initiation of T-EDTA. Lines were locked with a 1-ml solution for 2 h daily (T-EDTATPN, n = 17; T-EDTASBS, n = 48) and compared with our prior standard of care using 1.5-ml heparin flushes twice daily (CONTPN, n = 34; CONSBS, n = 48). Line patency and signs of sepsis were checked twice daily. Jugular catheters were replaced for occlusions whenever possible. Humane end points were used for sepsis not responding to antibiotic treatment or unresolved catheter occlusions.
Results: Compared with CON, sepsis was reduced using T-EDTA, significantly for TPN (P = 0.006) and with a trend for SBS piglets (P = 0.059). Line occlusions necessitating line changes were reduced 15% in TPN studies (P = 0.16), and no line occlusions occurred for T-EDTA SBS piglets.
Conclusion: In our neonatal piglet research, use of T-EDTA locking solution decreased sepsis and, although not statistically significant, reduced occlusions requiring line replacements. Given the expense of animal research, adding a locking solution must be cost-effective, and we were able to show that T-EDTA significantly reduced total research costs and improved animal welfare.
Keywords: gastroenterology; home nutrition support; liver disease; neonates; parenteral nutrition; pediatrics; sepsis; short bowel syndrome; venous access.
© 2024 American Society for Parenteral and Enteral Nutrition.
References
REFERENCES
-
- Lim DW, Turner JM, Wales PW. Emerging piglet models of neonatal short bowel syndrome. JPEN J Parenter Enteral Nutr. 2015;39(6):636‐643.
-
- Muto M, Kaji T, Onishi S, Yano K, Yamada W, Ieiri S. An overview of the current management of short‐bowel syndrome in pediatric patients. Surg Today. 2022;52(1):12‐21.
-
- Pauline M, Fouhse J, Hinchliffe T, et al. Probiotic treatment vs empiric oral antibiotics for managing dysbiosis in short bowel syndrome: Impact on the mucosal and stool microbiota, short‐chain fatty acids, and adaptation. JPEN J Parenter Enteral Nutr. 2022;46(8):1828‐1838.
-
- Belza C, Fitzgerald K, de Silva N, et al. Predicting intestinal adaptation in pediatric intestinal failure: a retrospective cohort study. Ann Surg. 2019;269(5):988‐993.
-
- Schalamon J, Mayr JM, Höllwarth ME. Mortality and economics in short bowel syndrome. Best Pract Res Clin Gastroenterol. 2003;17(6):931‐942.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
